SONAR propels endothelin A receptor antagonists to success.
SONAR propels endothelin A receptor antagonists to success.
复制标题
SONAR 推动内皮素 A 受体拮抗剂取得成功。
DOI：
10.1038/s41581-019-0169-9
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Pollock,DavidM
中科院分区：
文献类型：
--
作者：
Pollock,JenniferS;Pollock,DavidM
SONAR试验报告，选择性内皮素A受体拮抗剂阿曲生坦治疗可降低糖尿病和慢性肾脏疾病患者的肾脏事件风险。本研究旨在选择可能从治疗中获益的患者，并将不良反应的风险降至最低。
The SONAR trial reports that treatment with the selective endothelin A receptor antagonist atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease. This study was designed to select patients who were likely to benefit from the therapy and minimize the risk of adverse effects.